In CRC, proteomic analysis has demonstrated that downstream signaling molecules linked to KRAS mutations—such as proteins in the MAPK and PI3K-AKT pathways—show varying expression across different tumor subtypes, suggesting they could serve as promising new therapeutic targets (64). The gene discussed is KRAS; the disease is neoplasm.